News & Events

Johannes R. Kratz, M.D. and Yeranuí Ledesma, M.D. are among this year's recipients of the 2017 UCSF Health Exceptional Physician Award. Dr. Kratz, now a member of the Thoracic Oncology Program and Assistant Professor in the Division of Adult Cardiothoracic Surgery, and Dr. Ledesma, a Senior Resident in General...

The 28th Annual J. Engelbert Dunphy Resident Research Symposium was held on March 11, 2015 at Toland Hall. Jennifer Grandis, MD, Associate Vice Chancellor of Clinical and Translational Research, Director of Clincial and Translational Science Institute, and Professor of Otolaryngology-Head & Neck Surgery, gave the...

Building on earlier retrospective validation studies , a team of Thoracic Oncology Program researchers, demonstrated in a small prospective study the clinical utility of a 14-gene expression assay in stratifying risk among non-small cell lung cancer (NSCLC) patients. In a recently published paper in the journal...

Building on their earlier work reported in The Lancet, UCSF thoracic surgeon Michael Mann, M.D. (left), and Johannes Kratz, M.D. (right) a former surgical resident in the Thoracic Oncology Lab, showed they could accurately stratify patients even with the earliest stage of lung cancer into groups at low-...

The NIH has awarded two UCF scientists, Hassan Lemjabbar-Alaoui, Ph.D and Joanna J. Phillips, M.D., Ph.D., a five-year $2.2m grant to study the clinical utility of extracellular heparan sulfate endosulfatases, or SULFs, as biomarkers for early detection of non-small cell lung cancer (NSCLC) and malignant...

A team consisting of Hassan Lemjabbar-Alaoui, Ph.D., Assistant Adjunct Professor of Surgery and principal Investigator in the Thoracic Oncology Laboratory and Alaoui Lab, and Steven Rosen, PhD, Professor and Vice-chair of the Department of Anatomy, are developing a novel treatment for lung cancer in a unique...

Last October, opera singer Zheng Cao fell during a performance and had no idea why. Later, it turned out she had advanced lung cancer. Now, as a result of treatment with a new type of targeted therapy, her cancer is retreating. Personalized medicine - that is, customizing the treatment to the patient's tumor -is...

Adding their own contributions to a rapidly advancing field, UCSF researchers - along with colleagues from Incyte Corporation and the University of Texas Southwestern Medical Center - have described new targets in lung cancer and evaluated a promising new drug candidate that halts growth signals in tumor cells...